End-payors oppose Takeda judgment motion in US Amitiza antitrust case
MLex Summary: End-payor plaintiffs opposed Takeda Pharmaceuticals' motion for summary judgment on their US antitrust claims over Amitiza, arguing Takeda asks for reconsideration of a federal court's previous orders without grappling...To view the full article, register now.
Already a subscriber? Click here to view full article